Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

To see complete record on, please visit this link

Id: NCT05452772

Organisation Name: Johns Hopkins University

Overal Status: Not yet recruiting

Start Date: February 2023

Last Update: December 2, 2022

Lead Sponsor: Johns Hopkins University

Brief Summary: This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Three sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and either 150 mg or 200 mg in session 2), with sessions 1 week apart.

  • Tobacco Use Disorder

Total execution time in seconds: 0.31639695167542